FTH

SEC source: 0001415889-24-004236 · form4-02162024_110255.xml · nonDerivative · entry 1

van der Horst Edward · CIK 0001957499 · CHIEF SCIENTIFIC OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 56,070

F1 · kind: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units.

F2 · balance_after: Includes an aggregate of 6,000 shares purchased by the Reporting Person since May 16, 2023 pursuant to the Issuer's 2021 Employee Stock Purchase Plan.

SEC source: 0001415889-24-004234 · form4-02162024_110205.xml · derivative · entry 3

Colgan Erin · CIK 0001843563 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 94,128

Underlying: Common Stock · 94,128 shares

Expires 2034-02-14

F4 · derivative.exercise_date: Represents one-third of the Reporting Person's 2023 annual bonus, which the Compensation Committee of the Issuer determined to pay in the form of a stock option in lieu of cash. 100% of the shares are fully vested as of the date of grant.

SEC source: 0001415889-24-004234 · form4-02162024_110205.xml · derivative · entry 2

Colgan Erin · CIK 0001843563 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2034-02-14

F3 · derivative.exercise_date: The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 15, 2025, and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.

SEC source: 0001415889-24-004234 · form4-02162024_110205.xml · nonDerivative · entry 1

Colgan Erin · CIK 0001843563 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 67,462

F1 · kind: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units.

F2 · balance_after: Includes 3,000 shares purchased by the Reporting Person on May 16, 2023 pursuant to the Issuer's 2021 Employee Stock Purchase Plan.

SEC source: 0001415889-24-004235 · form4-02162024_110237.xml · derivative · entry 3

Celebi John · CIK 0001843539 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 165,889

Underlying: Common Stock · 165,889 shares

Expires 2034-02-14

F3 · derivative.exercise_date: Represents one-third of the Reporting Person's 2023 annual bonus, which the Compensation Committee of the Issuer determined to pay in the form of a stock option in lieu of cash. 100% of the shares are fully vested as of the date of grant.

SEC source: 0001415889-24-004235 · form4-02162024_110237.xml · derivative · entry 2

Celebi John · CIK 0001843539 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 315,000

Underlying: Common Stock · 315,000 shares

Expires 2034-02-14

F2 · derivative.exercise_date: The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 15, 2025, and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.

SEC source: 0001415889-24-004235 · form4-02162024_110237.xml · nonDerivative · entry 1

Celebi John · CIK 0001843539 · Director · PRESIDENT AND CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 105,420

F1 · kind: Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock units.

SEC source: 0001209191-23-054170 · doc4.xml · derivative · entry 1

Krebs Stephanie · CIK 0001998150 · Chief Business Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,000

Underlying: Common Stock · 125,000 shares

Expires 2033-10-31

F1 · derivative.exercise_date: The shares subject to the option vest and become exercisable as to 25% of the shares underlying the option on November 1, 2024, and the remaining 75% of the shares underlying the Option shall vest and become exercisable in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.

SEC source: 0001209191-23-049192 · doc4.xml · nonDerivative · entry 1

Celebi John · CIK 0001843539 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 111,311

SEC source: 0000897069-23-001054 · form4.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner · See Remarks

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,653,120

F1 · shares: Shares purchased by the Issuer pursuant to a Purchase Agreement, dated July 31, 2023, by and among the Issuer, the Reporting Person and James Peyer. This transaction, which was approved by the Board of Directors of the Issuer, is exempt pursuant to Rule 16b-3(e) of the Securities Exchange Act of 1934, as amended.

F2 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0000897069-23-001052 · form4.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 3,653,120

F1 · shares: Shares purchased by the Issuer pursuant to a Purchase Agreement, dated July 31, 2023, by and among the Issuer, the Reporting Person and Cambrian BioPharma Inc. This transaction, which was approved by the Board of Directors of the Issuer, is exempt pursuant to Rule 16b-3(e) of the Securities Exchange Act of 1934, as amended.

F2 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001209191-23-042103 · doc4.xml · derivative · entry 2

RINGO WILLIAM R · CIK 0001238325 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,550

Underlying: Common Stock · 14,550 shares

Expires 2033-07-09

F2 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or July 10, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001209191-23-042103 · doc4.xml · nonDerivative · entry 1

RINGO WILLIAM R · CIK 0001238325 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,399

F1 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or July 10, 2024, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001209191-23-042102 · doc4.xml · derivative · entry 3

RICKS THOMAS G · CIK 0001013023 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,550

Underlying: Common Stock · 14,550 shares

Expires 2033-07-09

F3 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or July 10, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001209191-23-042102 · doc4.xml · nonDerivative · entry 1

RICKS THOMAS G · CIK 0001013023 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,932

F1 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or July 10, 2024, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001209191-23-042101 · doc4.xml · derivative · entry 2

Broder Samuel · CIK 0001340543 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,550

Underlying: Common Stock · 14,550 shares

Expires 2033-07-09

F2 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or July 10, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001209191-23-042101 · doc4.xml · nonDerivative · entry 1

Broder Samuel · CIK 0001340543 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,932

F1 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or July 10, 2024, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001209191-23-042098 · doc4.xml · derivative · entry 2

Humer Kristian · CIK 0001872280 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,550

Underlying: Common Stock · 14,550 shares

Expires 2033-07-09

F2 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or July 10, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001209191-23-042098 · doc4.xml · nonDerivative · entry 1

Humer Kristian · CIK 0001872280 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,932

F1 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or July 10, 2024, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001209191-23-042097 · doc4.xml · derivative · entry 2

English Jessie · CIK 0001854515 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,550

Underlying: Common Stock · 14,550 shares

Expires 2033-07-09

F2 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or July 10, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001209191-23-042097 · doc4.xml · nonDerivative · entry 1

English Jessie · CIK 0001854515 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,932

F1 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or July 10, 2024, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001209191-23-042096 · doc4.xml · derivative · entry 2

Vojta Deneen · CIK 0001843509 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,550

Underlying: Common Stock · 14,550 shares

Expires 2033-07-09

F2 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or July 10, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001209191-23-042096 · doc4.xml · nonDerivative · entry 1

Vojta Deneen · CIK 0001843509 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,932

F1 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or July 10, 2024, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001209191-23-042095 · doc4.xml · derivative · entry 2

Holmen Bob · CIK 0001843508 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,550

Underlying: Common Stock · 14,550 shares

Expires 2033-07-09

F2 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or July 10, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001209191-23-042095 · doc4.xml · nonDerivative · entry 1

Holmen Bob · CIK 0001843508 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,598

F1 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or July 10, 2024, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

SEC source: 0001209191-23-042079 · doc4.xml · derivative · entry 2

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 14,550

Underlying: Common Stock · 14,550 shares

Expires 2033-07-09

F3 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or July 10, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

F2 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001209191-23-042079 · doc4.xml · nonDerivative · entry 1

Peyer James · CIK 0001843594 · Director · 10% owner

10b5-1 filing: No plan indicated

Ownership: Indirect · See footnote

Disclosed balance after: 5,240,422

F1 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or July 10, 2024, subject to the Reporting Person's continuous service with the Issuer through such vesting date.

F2 · ownership.nature: These shares are held by Cambrian Biopharma Inc, a Delaware corporation ("Cambrian"). The Reporting Person is the Chief Executive Officer of Cambrian and in such capacity may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001209191-23-042076 · doc4.xml · derivative · entry 2

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,550

Underlying: Common Stock · 14,550 shares

Expires 2033-07-09

F3 · derivative.exercise_date: The shares subject to the option vest and become exercisable in 12 equal monthly installments over a one year period such that the option is fully vested on the first anniversary of the date of grant, or July 10, 2024, subject to James Peyer's continuous service with the Issuer as of each such vesting date; provided that the option will in any case be fully vested on the date of the Company's next annual stockholder meeting, subject to James Peyer's continuous service with the Issuer through such vesting date.

F2 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0001209191-23-042076 · doc4.xml · nonDerivative · entry 1

Cambrian BioPharma Inc · CIK 0001797409 · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,240,422

F1 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in full on the first anniversary of the date of grant, or July 10, 2024, subject to the James Peyer's continuous service with the Issuer through such vesting date.

F2 · ownership.direct: These shares are held by Cambrian Biopharma, Inc., a Delaware corporation ("Cambrian"). The Chief Executive Officer of Cambrian, James Peyer, may direct the voting and disposition of the shares held by Cambrian, subject in certain instances to the approval of Cambrian's Board of Directors. Mr. Peyer disclaims beneficial ownership of such shares.

SEC source: 0000921895-23-001420 · form413506002_06022023.xml · nonDerivative · entry 2

Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner

Angermayer Christian · CIK 0001845872 · 10% owner

Presight Sensei Co-Invest Fund, L.P. · CIK 0001828422 · See Explanation of Responses

Presight Co-Invest Management, L.L.C. · CIK 0001846009 · See Explanation of Responses

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Presight Sensei Co-Invest Fund, L.P.

Disclosed balance after: 0

F1 · security: This Form 4 is filed jointly by Apeiron Investment Group Ltd. ("Apeiron"), Christian Angermayer, Presight Sensei Co-Invest Fund, L.P. ("Presight Co-Invest") and Presight Sensei Co-Invest Management, L.L.C. ("Presight Co-Invest Management", and collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that previously beneficially owned over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F3 · ownership.nature: Securities owned directly by Presight Co-Invest. As the general partner of Presight Co-Invest, Presight Co-Invest Management may be deemed to beneficially own the securities owned directly by Presight Co-Invest. As the sole member of Presight Co-Invest Management, Apeiron may be deemed to beneficially own the securities owned directly by Presight Co-Invest. Mr. Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities owned directly by Presight Co-Invest.

SEC source: 0000921895-23-001420 · form413506002_06022023.xml · nonDerivative · entry 1

Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner

Angermayer Christian · CIK 0001845872 · 10% owner

Presight Sensei Co-Invest Fund, L.P. · CIK 0001828422 · See Explanation of Responses

Presight Co-Invest Management, L.L.C. · CIK 0001846009 · See Explanation of Responses

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · By Apeiron Investment Group Ltd.

Disclosed balance after: 0

F1 · security: This Form 4 is filed jointly by Apeiron Investment Group Ltd. ("Apeiron"), Christian Angermayer, Presight Sensei Co-Invest Fund, L.P. ("Presight Co-Invest") and Presight Sensei Co-Invest Management, L.L.C. ("Presight Co-Invest Management", and collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that previously beneficially owned over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F2 · ownership.nature: Securities owned directly by Apeiron. Mr. Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities owned directly by Apeiron.

SEC source: 0000921895-23-000615 · form413506002_02272023.xml · nonDerivative · entry 2

Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner

Angermayer Christian · CIK 0001845872 · 10% owner

Presight Sensei Co-Invest Fund, L.P. · CIK 0001828422 · See Explanation of Responses

Presight Co-Invest Management, L.L.C. · CIK 0001846009 · See Explanation of Responses

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Apeiron Investment Group Ltd.

Disclosed balance after: 2,485,923

F1 · security: This Form 4 is filed jointly by Apeiron Investment Group Ltd. ("Apeiron"), Christian Angermayer, Presight Sensei Co-Invest Fund, L.P. ("Presight Co-Invest") and Presight Sensei Co-Invest Management, L.L.C. ("Presight Co-Invest Management", and collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that beneficially owns over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F2 · ownership.nature: Securities owned directly by Apeiron. Mr. Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities owned directly by Apeiron.

SEC source: 0000921895-23-000615 · form413506002_02272023.xml · nonDerivative · entry 1

Apeiron Investment Group Ltd. · CIK 0001845711 · 10% owner

Angermayer Christian · CIK 0001845872 · 10% owner

Presight Sensei Co-Invest Fund, L.P. · CIK 0001828422 · See Explanation of Responses

Presight Co-Invest Management, L.L.C. · CIK 0001846009 · See Explanation of Responses

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By Apeiron Investment Group Ltd.

Disclosed balance after: 2,484,823

F1 · security: This Form 4 is filed jointly by Apeiron Investment Group Ltd. ("Apeiron"), Christian Angermayer, Presight Sensei Co-Invest Fund, L.P. ("Presight Co-Invest") and Presight Sensei Co-Invest Management, L.L.C. ("Presight Co-Invest Management", and collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group that beneficially owns over 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.

F2 · ownership.nature: Securities owned directly by Apeiron. Mr. Angermayer, as the majority shareholder of Apeiron, may be deemed to beneficially own the securities owned directly by Apeiron.

SEC source: 0001209191-23-010736 · doc4.xml · derivative · entry 3

van der Horst Edward · CIK 0001957499 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 75,000 shares

Expires 2033-02-14

F3 · derivative.exercise_date: The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 15, 2024, and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.

SEC source: 0001209191-23-010736 · doc4.xml · nonDerivative · entry 2

van der Horst Edward · CIK 0001957499 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,438

F2 · shares: These shares represent RSUs. Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in four equal annual installments on each of February 15, 2024, February 15, 2025, February 15, 2026 and February 15, 2027, subject to the Reporting Person's continuous service with the Issuer as of each such date.

SEC source: 0001209191-23-010736 · doc4.xml · nonDerivative · entry 1

van der Horst Edward · CIK 0001957499 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 44,738

F1 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs are fully vested.

SEC source: 0001209191-23-010734 · doc4.xml · derivative · entry 3

Gallagher Patrick Stephen · CIK 0001932215 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2023-02-14

F3 · derivative.exercise_date: The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 15, 2024, and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.

SEC source: 0001209191-23-010734 · doc4.xml · nonDerivative · entry 2

Gallagher Patrick Stephen · CIK 0001932215 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,515

F2 · shares: These shares represent RSUs. Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in four equal annual installments on each of February 15, 2024, February 15, 2025, February 15, 2026 and February 15, 2027, subject to the Reporting Person's continuous service with the Issuer as of each such date.

SEC source: 0001209191-23-010734 · doc4.xml · nonDerivative · entry 1

Gallagher Patrick Stephen · CIK 0001932215 · Chief Business Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,313

F1 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs are fully vested.

SEC source: 0001209191-23-010735 · doc4.xml · derivative · entry 3

Colgan Erin · CIK 0001843563 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2033-02-14

F3 · derivative.exercise_date: The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 15, 2024, and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.

SEC source: 0001209191-23-010735 · doc4.xml · nonDerivative · entry 2

Colgan Erin · CIK 0001843563 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,032

F2 · shares: These shares represent RSUs. Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in four equal annual installments on each of February 15, 2024, February 15, 2025, February 15, 2026 and February 15, 2027, subject to the Reporting Person's continuous service with the Issuer as of each such date.

SEC source: 0001209191-23-010735 · doc4.xml · nonDerivative · entry 1

Colgan Erin · CIK 0001843563 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,732

F1 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs are fully vested.

SEC source: 0001209191-23-010731 · doc4.xml · derivative · entry 3

Celebi John · CIK 0001843539 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2033-02-14

F3 · derivative.exercise_date: The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 15, 2024, and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.

SEC source: 0001209191-23-010731 · doc4.xml · nonDerivative · entry 2

Celebi John · CIK 0001843539 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 127,307

F2 · shares: These shares represent RSUs. Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in four equal annual installments on each of February 15, 2024, February 15, 2025, February 15, 2026 and February 15, 2027, subject to the Reporting Person's continuous service with the Issuer as of each such date.

SEC source: 0001209191-23-010731 · doc4.xml · nonDerivative · entry 1

Celebi John · CIK 0001843539 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 106,007

F1 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs are fully vested.

SEC source: 0001209191-23-021542 · doc4a.xml · derivative · entry 3

Colgan Erin · CIK 0001843563 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2033-02-14

F5 · derivative.exercise_date: The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 15, 2024, and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.

SEC source: 0001209191-23-021542 · doc4a.xml · nonDerivative · entry 2

Colgan Erin · CIK 0001843563 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,032

F4 · shares: These shares represent RSUs. Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in four equal annual installments on each of February 15, 2024, February 15, 2025, February 15, 2026 and February 15, 2027, subject to the Reporting Person's continuous service with the Issuer as of each such date.

F1 · balance_after: This amendment is being filed solely to correct the number of shares beneficially owned. Due to administrative error the original filing did not include shares purchased under the Issuer's Employee Stock Purchase Plan ("ESPP").

F3 · balance_after: Share balance includes stock purchased under the ESPP not previously reported.

SEC source: 0001209191-23-021542 · doc4a.xml · nonDerivative · entry 1

Colgan Erin · CIK 0001843563 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,732

F1 · security: This amendment is being filed solely to correct the number of shares beneficially owned. Due to administrative error the original filing did not include shares purchased under the Issuer's Employee Stock Purchase Plan ("ESPP").

F2 · shares: These shares represent restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs are fully vested.

F1 · balance_after: This amendment is being filed solely to correct the number of shares beneficially owned. Due to administrative error the original filing did not include shares purchased under the Issuer's Employee Stock Purchase Plan ("ESPP").

F3 · balance_after: Share balance includes stock purchased under the ESPP not previously reported.

SEC source: 0001209191-23-021541 · doc4a.xml · derivative · entry 3

Celebi John · CIK 0001843539 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 90,000

Underlying: Common Stock · 90,000 shares

Expires 2033-02-14

F5 · derivative.exercise_date: The option shall vest over a period of four years as follows: 25% of the total number of shares subject to the option shall vest on February 15, 2024, and the remainder will vest 1/48th of total number of shares subject to the option monthly thereafter over the remaining three years, subject to the Reporting Person's continuous service with the Issuer as of each such date.

SEC source: 0001209191-23-021541 · doc4a.xml · nonDerivative · entry 2

Celebi John · CIK 0001843539 · Director · President and CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 131,303

F4 · shares: These shares represent RSUs. Each RSU represents a contingent right to receive one share of the common stock of the Issuer. The shares underlying the RSUs vest in four equal annual installments on each of February 15, 2024, February 15, 2025, February 15, 2026 and February 15, 2027, subject to the Reporting Person's continuous service with the Issuer as of each such date.

F1 · balance_after: This amendment is being filed solely to correct the number of shares beneficially owned. Due to administrative error the original filing did not include shares purchased under the Issuer's Employee Stock Purchase Plan ("ESPP").

F3 · balance_after: Share balance includes stock purchased under the ESPP not previously reported.